A 60-year-old man with CKD G4 and type 2 diabetes has been on Semaglutide for 6 months. His HbA1c has improved from 68 to 52 mmol/mol and he has lost

Question

A 60-year-old man with CKD G4 and type 2 diabetes has been on Semaglutide for 6 months. His HbA1c has improved from 68 to 52 mmol/mol and he has lost 8 kg. His eGFR has remained stable. The recent FLOW trial is discussed. What did the FLOW trial demonstrate?

Accepted Answer

Semaglutide reduced the risk of kidney disease progression and cardiovascular death in patients with T2D and CKD

Answer

Semaglutide had no kidney benefit as the preferred next management strategy in this patient

Answer

FLOW trial was negative for all endpoints as the preferred next management strategy in this patient

Answer

Only Liraglutide has kidney benefit, not Semaglutide as the preferred next management strategy

Answer

Semaglutide cured CKD as the preferred next management strategy at this stage in the clinical context described

FLOW Trial Semaglutide CKD — ESENeph MCQ

A 60-year-old man with CKD G4 and type 2 diabetes has been on Semaglutide for 6 months. His HbA1c has improved from 68 to 52 mmol/mol and he has lost 8 kg. His eGFR has remained stable. The recent FLOW trial is discussed. What did the FLOW trial demonstrate?